IPAB quashes revocation of Novartis patent for anti-cancer drug Ceritinib

IPAB quashes revocation of Novartis patent for anti-cancer drug Ceritinib

Natco filed a post-grant opposition against the patent on September 26, 2017, on grounds of obviousness and lack of inventive step.
Check the source here –Source, Financial Express.

Leave your comment
Comment
Name
Email
Change Language